HR Execs on the Move

Reneo Pharmaceuticals

www.reneopharma.com

 
Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Gregory Flesher
 President and Chief Executive Officer Profile
Jennifer Lam
 VP of Finance and Administration Profile

Similar Companies

Chi Botanic

Changing how we grow with plant cell cultures.

Floyd County Memorial Hospital

Floyd County Memorial Hospital is a Charles City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arbor Vita Corporation

Arbor Vita Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AngioScore

AngioScore is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunoGen

Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.